Article Text

PDF
Letter
Prevalence of serrated polyposis syndrome in an FIT-based colorectal cancer screening cohort in Italy
  1. Dora Colussi1,
  2. Rocco Maurizio Zagari1,
  3. Beatrice Morini1,
  4. Margherita Fabbri1,
  5. Amedeo Montale1,
  6. Cesare Hassan2,
  7. Carlo Senore3,
  8. Franco Bazzoli1,
  9. Luigi Ricciardiello1,4
  1. 1 Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
  2. 2 Endoscopy Unit, Nuovo Regina Margherita Hospital, Rome, Italy
  3. 3 Città della Salute e della Scienza University Hospital, SCDO Epidemiology, Screening, Cancer Registry, CPO, Turin, Italy
  4. 4 Center for the Research on Hereditary Cancers, University of Bologna, Bologna, Italy
  1. Correspondence to Dr Luigi Ricciardiello, Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, PAD.11, Bologna 40138, Italy; luigi.ricciardiello{at}unibo.it

Statistics from Altmetric.com

To the Editor

We read with interest the recent data reported by IJspeert et al,1 Biswas et al 2 and Moreira et al 3 whom evaluated the prevalence of serrated polyposis syndrome (SPS), a disease characterised by the development of multiple serrated polyps throughout the colon with an increased risk to develop colorectal cancer (CRC),4 inside CRC screening programmes. A guaiac faecal occult blood test cohort from the UK showed a frequency of SPS ranging from 0.03% to 0.66%.1 ,2 Other cohorts based on primary colonoscopy showed a prevalence of SPS between 0.1% and 0.4%.1 The only published data on SPS frequency within faecal immunochemical test (FIT) programmes are from Spain and ranged from 0.34% to 0.8%.1 ,3 Since FIT has widely become the method of choice for …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.